Meletiadis Joseph, Stergiopoulou Theodouli, O'Shaughnessy Elizabeth M, Peter Joanne, Walsh Thomas J
National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA.
Antimicrob Agents Chemother. 2007 Jun;51(6):2053-64. doi: 10.1128/AAC.00873-06. Epub 2007 Mar 26.
Triple antifungal combinations are used against refractory invasive aspergillosis without an adequate understanding of their pharmacodynamic interactions. We initially studied the in vitro triple combination of voriconazole, amphotericin B, and caspofungin against Aspergillus fumigatus, A. flavus, and A. terreus by a spectrophotometric microdilution broth method after 48 h of incubation. We then analyzed these results with a recently described nonlinear mixture response surface E(max)-based model modified to assess pharmacodynamic interactions at various growth levels. The new model allows flexibility in all four parameters of the E(max) model and is able to describe complex pharmacodynamic interactions. Concentration-dependent pharmacodynamic interactions were found within the triple antifungal combination. At the 50% growth level, synergy (median interaction indices of 0.43 to 0.82) was observed at low concentrations of voriconazole (<0.03 mg/liter) and amphotericin B (</=0.20 mg/liter) and at intermediate concentrations of caspofungin (0.95 to 14.88 mg/liter), whereas antagonism (median interaction indices of 1.17 to 1.80) was found at higher concentrations of voriconazole and amphotericin B. Ternary plot and interaction surface analysis further revealed the complexity of these concentration-dependent interactions. With increasing concentrations of amphotericin B, the synergistic interactions of voriconazole-caspofungin double combination decreased while the antagonistic interactions increased. A similar effect was observed when voriconazole was added to the double combination of amphotericin B and caspofungin. In conclusion, the new nonlinear mixture-amount response surface modeling of the triple antifungal combination demonstrated a net antagonism or synergy against Aspergillus species depending upon drug concentrations and species.
三药联合抗真菌方案用于治疗难治性侵袭性曲霉病,但对其药效学相互作用却缺乏充分了解。我们最初采用分光光度微量稀释肉汤法,在孵育48小时后,研究伏立康唑、两性霉素B和卡泊芬净对烟曲霉、黄曲霉和土曲霉的体外三联组合效果。然后,我们使用最近描述的基于E(max)的非线性混合反应表面模型对这些结果进行分析,该模型经过修改以评估不同生长水平下的药效学相互作用。新模型在E(max)模型的所有四个参数上具有灵活性,能够描述复杂的药效学相互作用。在三联抗真菌组合中发现了浓度依赖性药效学相互作用。在50%生长水平时,在低浓度伏立康唑(<0.03毫克/升)和两性霉素B(≤0.20毫克/升)以及中等浓度卡泊芬净(0.95至14.88毫克/升)时观察到协同作用(中位相互作用指数为0.43至0.82),而在较高浓度的伏立康唑和两性霉素B时发现拮抗作用(中位相互作用指数为1.17至1.80)。三元图和相互作用表面分析进一步揭示了这些浓度依赖性相互作用的复杂性。随着两性霉素B浓度的增加,伏立康唑-卡泊芬净双联组合的协同相互作用降低,而拮抗相互作用增加。当将伏立康唑添加到两性霉素B和卡泊芬净的双联组合中时也观察到类似效果。总之,三联抗真菌组合的新非线性混合量反应表面模型表明,根据药物浓度和菌种不同,对曲霉属菌种有净拮抗或协同作用。